Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.